MiraVista Institutional Biosafety Committee (IBC) Announcement

In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure...

Test Report Updates for 2021

In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative...

Are You Underdiagnosing Coccidioidomycosis?

Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2%...

Only Available at MiraVista Diagnostics: MycoMEIA® Aspergillus Galf Urine EIA
MiraVista Diagnostics now offers MycoMEIA® Aspergillus Galf Urine EIA, a urine-based antigen assay that complements serum galactomannan (GM) testing and may improve diagnostic confidence for invasive aspergillosis (IA).

X